Cell Proliferation · 2019 · 36 citations · 31 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyMolecular PharmacologyCancer BiomarkersGenitourinary Cancer PharmacotherapyMitochondrial ToxicityOncology PharmacologyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAnticancer ActivityApoptosis InductionAtp Production ReductionDiamidine TreatmentMitochondrial Dna DeletionsMitochondrial Dna MarkersMitochondrial Membrane Potential CollapseMitochondrial Membrane Potential Maintenance
OBJECTIVES: We investigated the anti-cancer activity of pentamidine, an anti-protozoal cationic aromatic diamidine drug, in prostate cancer cells and aimed to provide valuable insights for improving the efficacy of prostate cancer treatment. MATERIALS AND METHODS: Prostate cancer cell lines and epithelial RWPE-1 cells were used in the study. Cell viability, wound-healing, transwell and apoptosis assays were examined to evaluate the influences of pentamidine in vitro. RNA-seq and qPCR were performed to analyse changes in gene transcription levels upon pentamidine treatment. Mitochondrial changes were assessed by measuring mitochondrial DNA content, morphology, membrane potential, cellular glucose uptake, ATP production and ROS generation. Nude mouse xenograft models were used to test anti-tumour effects of pentamidine in vivo. RESULTS: Pentamidine exerted profound inhibitory effects on proliferation, colony formation, migration and invasion of prostate cancer cells. In addition, the drug suppressed growth of xenograft tumours without exhibiting any obvious toxicity in nude mice. Mechanistically, pentamidine caused mitochondrial DNA content reduction and induced mitochondrial morphological changes, mitochondrial membrane potential dissipation, ATP level reduction, ROS production elevation and apoptosis in prostate cancer cells. CONCLUSIONS: Pentamidine can efficiently suppress prostate cancer progression and may serve as a novel mitochondria-targeted therapeutic agent for prostate cancer.
31
Sequence and organization of the human mitochondrial genome
Stephen K. Anderson, Alan T. Bankier, B. G. Barrell et al. · Nature · 1981 · 9.7K citations
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · New England Journal of Medicine · 2014 · 3K citations · Full text
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +17